Study on One-Time Methadone During Minimally Invasive Hysterectomy to Reduce Opioid Use

What this Trial Is About

Researchers are studying the best pain medication plan during and after laparoscopic hysterectomy to reduce long-term opioid use. The trial focuses on comparing intraoperative single-dose methadone, a longer-acting opioid, with standard short-acting opioids to address the problem of opioid overprescribing after surgery. The goal is to find a safer, more effective way to manage postoperative pain and reduce the risk of opioid abuse. The study involves two groups one receives a single intraoperative dose of intravenous methadone based on ideal body weight, while the other group receives the usual short-acting opioids during surgery. Both groups undergo minimally invasive hysterectomy, either laparoscopic or robotic, with ovarian preservation. Researchers will monitor participants during the postoperative period to evaluate pain control and opioid use. Participants will be assessed for total postoperative opioid requirements over one week, along with mobility, satisfaction with pain relief, and any unplanned healthcare visits related to pain during the first week after surgery. The study includes follow-ups on postoperative days 1 and 7 to evaluate pain management and patient satisfaction. The trial aims to reduce additional opioid prescriptions and improve recovery after hysterectomy.

The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription.